Drug Profile

BAY 1158061

Alternative Names: Anti-prolactin receptor monoclonal antibody - Bayer/Hope Medicine; BAY1158061; HMI-115

Latest Information Update: 28 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bayer
Developer Bayer; Hope Medicine
Class Monoclonal antibodies; Skin disorder therapies
Mechanism of Action Prolactin receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Alopecia; Endometriosis

Most Recent Events

28 Jun 2025 No recent reports of development identified for phase-I development in Alopecia in Australia (SC, Injection)
28 Nov 2024 Hope Medicine completes a phase II clinical trial in Alopecia in China (SC) (NCT06118866)
24 Oct 2024 BAY 1158061 receives Breakthrough Therapy status for Endometriosis in China

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com